Issued 2026-08-13 at $98.97 · now $98.77 (2026-08-13, −0.2% since)
Based on its own history, a month from the 2026-08-13 close, MIRM has typically landed between $82.86 and $126.09 — a range of −16.3% to +27.4% from the issuance price $98.97.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,756 overlapping 1 month windows · 2019-07-18 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($98.97) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where MIRM has typically landed a month from the 2026-08-13 close of $98.97 — the range is history, not a prediction.
- now $98.77 (-0.2%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $101.77 (+2.8%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $92.62–$110.92
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $82.86–$126.09
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2020-02-18 | −45.6% | −45.6% | +7.1% |
| 2020-02-19 | −40.3% | −48.1% | +2.0% |
| 2020-02-13 | −39.0% | −39.0% | +8.1% |
| 3 best | |||
| 2019-11-25 | +272.7% | +0.0% | +272.7% |
| 2019-11-22 | +255.6% | −1.8% | +255.6% |
| 2019-11-26 | +251.4% | +0.0% | +264.8% |
1,756 overlapping windows · 2019-07-18 – 2026-08-13 · not cherry-picked
Pending catalysts
- October 2026 — Trial primary completion: Phase 3 primary completion: Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) (source, as of 2026-08-14)
- April 2027 — Trial primary completion: Phase 2 primary completion: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis (source, as of 2026-08-14)
- 2027-06-30 — Trial primary completion: Phase 3 primary completion: A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) (source, as of 2026-08-14)
- 2027-08-31 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide (source, as of 2026-08-14)
- October 2027 — Trial primary completion: Phase 2 primary completion: Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) (source, as of 2026-08-14)
- May 2029 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~8 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.